18 studies found for:    Open Studies | "Pneumococcal Infections"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)
Conditions: Streptococcus Pneumoniae Infection;   Pneumococcal Infections
Interventions: Biological: V114;   Biological: Prevnar 13
2 Recruiting Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
Conditions: Pneumococcal Infections;   Pneumonia, Pneumococcal
Interventions: Biological: GEN-004 with Aluminum Hydroxide Adjuvant;   Biological: Placebo
3 Recruiting A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Condition: Pneumococcal Infection
Intervention: Biological: Prevnar 13 (PVC13)
4 Recruiting Aerosolized and Intravenous Colistin in Healthy Adults
Conditions: Pneumonia;   Pneumococcal Infection;   Pathogen Resistance
Interventions: Drug: Colistimethate (Colistin)Sodium-Aerosolized;   Drug: Colistimethate (Colistin)Sodium-Intravenous
5 Not yet recruiting Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
Conditions: HIV;   Pneumococcal Infections;   Pneumococcal Vaccines
Interventions: Biological: PCV-13;   Biological: PPSV-23
6 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection
Condition: Infections, Streptococcal
Intervention: Biological: Synflorix™
7 Not yet recruiting Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)
Condition: Pneumococcal Infection
Intervention: Biological: PNEUMOVAX™ 23
8 Recruiting Systems Biology of 23-valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®)
Condition: Pneumococcal Infection
Interventions: Biological: PNEUMOVAX and PREVNAR;   Biological: Pneumovax or Prevnar
9 Not yet recruiting An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department
Condition: Pneumococcal Infections
Intervention:
10 Recruiting A Study to Evaluate the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)
Condition: Pneumococcal Infections
Interventions: Biological: Prevnar 13™;   Biological: Pneumovax™ 23;   Biological: Placebo
11 Unknown  PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease
Conditions: Middle Ear Effusion;   Tympanic Membrane Perforation;   Acute Otitis Media;   Pneumococcal Infections
Intervention: Biological: 23 valent pneumococcal polysaccharide vaccine
12 Recruiting Protection Against Pneumococcal Infection in Children With T1DM
Condition: Type 1 Diabetes Mellitus
Intervention: Biological: 13-valent pneumococcal conjugate vaccine (PCV13)
13 Not yet recruiting System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts
Conditions: Influenza;   Infections, Pneumococcal
Interventions: Other: Arm 1: E-portal message with IVR call;   Other: Arm 2: E-portal message with no IVR call;   Other: Arm 3: No e-portal message with IVR call;   Other: Arm 5: IVR call
14 Not yet recruiting Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD
Conditions: Infections, Pneumococcal;   Bowel Diseases, Inflammatory
Interventions: Biological: Prevenar 13;   Biological: Pneumo 23
15 Not yet recruiting Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
Condition: Pneumonia, Pneumococcal
Interventions: Biological: PATH-wSP;   Biological: pneumococcal polysaccharide conjugate vaccine (adsorbed);   Biological: Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate;   Other: Saline
16 Recruiting Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.
Conditions: Seizures;   Pneumococcal Meningitis
Interventions: Drug: Phenytoin;   Drug: placebo
17 Recruiting Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older
Condition: Influenza
Interventions: Biological: Influsplit™ Tetra (Fluarix™ Tetra);   Biological: Pneumovax 23/Pneumovax;   Biological: Placebo
18 Recruiting Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults
Condition: Splenectomized Patients
Intervention: Biological: Prime-boost pneumococcal immunization

Indicates status has not been verified in more than two years